Aurora: Investor Presentation

Scientific Leadership Advantage Strong Science & Innovation Team to Driving Medical Advancements Shane Morris, PhD Chief Product Officer Experienced executive in the cannabis industry since 2015; previously part of the senior leadership team at Hydropothecary Jon Page, PhD Chief Science Officer UNIVERSITY OF MANITOBA First scientist to sequence the cannabis genome and provide deep insights into the biosynthesis of cannabinoids Jason Dyck, PhD Human Scientist, Director Professor in the Department of Pediatrics at the University of Alberta and a Canada Research Chair in Molecular Medicine Partnering with Leading Institutions and Universities 19 & UBC THE UNIVERSITY OF BRITISH COLUMBIA Kelly Narine, PhD Head of Biomedical Research Canada ARC CIRC PhD in Medical Genetics from the University of Alberta; Deep expertise in translating research into positive health outcomes UNIVERSITY OF TORONTO 1. Studies include randomized clinical trials and observational studies in addition to several case studies. de for McGill UNIVERSITY UNIVERSITY OF SASKATCHEWAN 40 7 Pre-Clinical Studies in Progress 27 Clinical Studies Currently Under Discussion Clinical Studies Underway or Completed(1) With Strong IP Retention on Clinical Studies Clinical Research Areas include: Pain, Epilepsy, PTSD, Anxiety, Opioid Sparing, Cancer, Neurodegeneration Mount Sinai Hospital Sinal Health System Joseph & Wolf Lebosic Health Complec Mater camh Centre for Addiction indent Cet de ser m AURORA 16

View entire presentation